- Parc Taulí, one of the three leading centers in Cystic Fibrosis in Catalonia, together with the Vall d'Hebron and Sant Joan de Déu hospitals in Barcelona, will administer the Kaftrio® drug. Four patients from Parc Taulí have participated in the clinical trial of this treatment.
- The drug will be included in the National Health System from December 1. It is a revolutionary treatment that slows down the deterioration of Cystic Fibrosis.
In Parc Taulí, one of the three leading centers in Catalonia for the treatment of Cystic Fibrosis (CF), together with the Hospital Vall d'Hebron and Sant Joan de Déu in Barcelona, the announcement of the approval of the drug Kaftrio®, meaning for its patients. It is a revolutionary drug, which slows down the deterioration caused by the disease and will change the lives of 70-75% of the CF population across the state.
The coordinator of the Cystic Fibrosis Unit of Parc Taulí, Òscar Asensio, who is the president of the Spanish CF Society and vice-president of the Spanish CF Foundation, does not hide his great satisfaction with this announcement from the Ministry of Health. "It was urgent to incorporate this drug into the portfolio of Cystic Fibrosis treatments due to its extraordinary results," explains Asensio, who highlights how, in Parc Taulí, we have seen that it changes patients' lives by improving their lung function. substantially and how patients with advanced involvement can leave the list of lung transplants ”· This has been confirmed thanks to the fact that Parc Taulí has participated in the Kaftrio® clinical trial with the inclusion of four patients .
The Ministry has already announced that the medicine will be available in the National Health System from 1 December, although the specific date in each autonomous community may vary. As a reference center, Parc Taulí will be one of the three Catalan hospitals that will be able to manage it, through its Hospital Pharmacy Service.
About 85 affected people, children and adults, are currently being monitored at Parc Taulí. In the last year, 2 new cases have been diagnosed in this center using thescreening methods neonatal and another late diagnosis of a mild case of an adult who in his day had not been able to benefit from neonatal screening.
Cystic Fibrosis is the most common inherited genetic disease in Catalonia that severely and progressively affects the respiratory, digestive and reproductive systems of people who suffer from it. CF, which currently affects one in 6.700 babies, does not have a curative treatment, although the drug Kaftrio® will be a before and after for a significant portion of those affected.
Between 11 and 13 November will take place on Congress of the Spanish Society of Cystic Fibrosis, which will be chaired by Dr. Asensio. No doubt all participants will have a great reason to celebrate this year.
More information:
> Spanish Society of Cystic Fibrosis
Leave a Reply